Search

Your search keyword '"Afrough, Aimaz"' showing total 288 results
Start Over Author "Afrough, Aimaz"
288 results on '"Afrough, Aimaz"'

1. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Author

Zanwar, Saurabh, Sidana, Surbhi, Shune, Leyla, Puglianini, Omar Castaneda, Pasvolsky, Oren, Gonzalez, Rebecca, Dima, Danai, Afrough, Aimaz, Kaur, Gurbakhash, Davis, James A., Herr, Megan, Hashmi, Hamza, Forsberg, Peter, Sborov, Douglas, Anderson Jr, Larry D., McGuirk, Joseph P., Wagner, Charlotte, Lieberman-Cribbin, Alex, Rossi, Adriana, Freeman, Ciara L., Locke, Frederick L., Richard, Shambavi, Khouri, Jack, Lin, Yi, Patel, Krina K., Kumar, Shaji K., and Hansen, Doris K.

Published
2024
Full Text
View/download PDF

2. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, Hashmi, Hamza, Hansen, Doris K., Sidana, Surbhi, Ahn, Chul, Peres, Lauren C., Dima, Danai, Freeman, Ciara L., Puglianini, Omar Castaneda, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter M., Shune, Leyla, McGuirk, Joseph P., Simmons, Gary, Sborov, Douglas W., Davis, James A., Kaur, Gurbakhash, Sannareddy, Aishwarya, Ferreri, Christopher J., Gaballa, Mahmoud R., Goldsmith, Scott, Nadeem, Omar, Midha, Shonali, Wagner, Charlotte B., Locke, Frederick L., Patel, Krina K., Khouri, Jack, Anderson, Jr., Larry D., and Lin, Yi

Published
2024
Full Text
View/download PDF

5. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy

Author

Greenbaum, URI, primary, Ramdial, JEREMY L., additional, Afrough, AIMAZ, additional, Alsfeld, LEONARD C., additional, Ghanem, SASSINE, additional, Daher, MAY, additional, Olson, AMANDA, additional, Kebriaei, PARTOW, additional, Strati, PAOLO, additional, Steiner, RAPHAEL E., additional, Ahmed, SAIRAH, additional, Tanner, MARK R., additional, Neelapu, SATTVA S., additional, Rezvani, KATAYOUN, additional, and Shpall, ELIZABETH J., additional

Published
2024
Full Text
View/download PDF

6. List of Contributors

Author

Rahman, Zaid Abdel, primary, Abutalib, Syed Ali, additional, Afrough, Aimaz, additional, Ahmed, Sairah, additional, Al-Juhaishi, Taha, additional, Alousi, Amin M, additional, Alsfeld, Leonard C., additional, Awan, Farrukh T., additional, Azhar, Ahsan, additional, Bashir, Qaiser, additional, Brown, Brandon Douglas, additional, Cao, Kai, additional, Champlin, Richard E., additional, Cherng, Hua-Jay J., additional, Ciurea, Stefan O., additional, Dabaja, Bouthaina, additional, Daher, May, additional, De Lima, Marcos, additional, Dillard, Christen M., additional, Fang, Penny, additional, Viña, Marcelo A. Fernández, additional, Ferreri, Christopher James, additional, Furqan, Fateeha, additional, Gagelmann, Nico, additional, Geethakumari, Praveen Ramakrishnan, additional, Ghanem, Sassine, additional, Greenbaum, Uri, additional, Gulbis, Alison M., additional, Haider, Ali, additional, Hamadani, Mehdi, additional, Handy, Victoria Wehr, additional, Hawkins, Misha C., additional, Heredia, Ella J. Ariza, additional, Hosing, Chitra, additional, Im, Jin Seon, additional, Jain, Nitin, additional, Jallouk, Andrew P, additional, Jankowski, Mika L., additional, Kale, Brandon J., additional, Kebriaei, Partow, additional, Khalil, Lana, additional, Khan, Irum, additional, Khazal, Sajad, additional, Kongtim, Piyanuch, additional, Lin, Paul, additional, Mahadeo, Kris M., additional, Malek, Alexandre E, additional, McGee, Kara, additional, Mehta, Rohtesh S., additional, Mulanovich, Victor Eduardo, additional, Munshi, Pashna N., additional, Nastoupil, Loretta J., additional, Neelapu, Sattva S, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Otegbeye, Folashade, additional, Patel, Akshat Maneesh, additional, Patel, Krina, additional, Paul, Prince, additional, Pemmaraju, Naveen, additional, Popat, Uday R, additional, Qazilbash, Muzaffar H., additional, Rafei, Hind, additional, Ragoonanan, Dristhi S, additional, Ramdial, Jeremy L., additional, Rezvani, Katayoun, additional, Rodriguez, Ana Avila, additional, Rondón, Gabriela, additional, Saengboon, Supawee, additional, Sanchez-Petitto, Gabriela, additional, Shigle, Terri Lynn, additional, Shpall, Elizabeth J., additional, Srour, Samer A., additional, Steiner, Raphael E., additional, Stolar, Karen R., additional, Strati, Paolo, additional, Szewczyk, Nicholas A., additional, Tanner, Mark R., additional, Tang, Kevin, additional, Thall, Peter F., additional, Tummala, Sudhakar, additional, Uzoka, Chukwuemeka, additional, Wallis, Whitney D., additional, Westin, Jason R., additional, Wilson, Nathaniel R., additional, Wu, Susan, additional, Guevara, Eduardo Yepez, additional, and Zou, Jun, additional

Published
2024
Full Text
View/download PDF

7. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Author

Ferreri, Christopher J., Hildebrandt, Michelle A. T., Hashmi, Hamza, Shune, Leyla O., McGuirk, Joseph P., Sborov, Douglas W., Wagner, Charlotte B., Kocoglu, M. Hakan, Rapoport, Aaron, Atrash, Shebli, Voorhees, Peter M., Khouri, Jack, Dima, Danai, Afrough, Aimaz, Kaur, Gurbakhash, Anderson, Jr., Larry D., Simmons, Gary, Davis, James A., Kalariya, Nilesh, Peres, Lauren C., Lin, Yi, Janakiram, Murali, Nadeem, Omar, Alsina, Melissa, Locke, Frederick L., Sidana, Surbhi, Hansen, Doris K., Patel, Krina K., and Castaneda Puglianini, Omar Alexis

Published
2023
Full Text
View/download PDF

8. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy

Author

Peres, Lauren C., Oswald, Laura B., Dillard, Christen M., De Avila, Gabriel, Nishihori, Taiga, Blue, Brandon J., Freeman, Ciara L., Locke, Frederick L., Alsina, Melissa, Castaneda Puglianini, Omar, Shune, Leyla, Sborov, Douglas W., Wagner, Charlotte, Dima, Danai, Hashmi, Hamza, Davis, James A., Kocoglu, Mehmet H., Badros, Ashraf Z., Atrash, Shebli, Simmons, Gary, Kalariya, Nilesh, Ferreri, Christopher, Anderson, Larry D., Jr, Afrough, Aimaz, Kaur, Gurbakhash, Lin, Yi, Liu, Lawrence, Nadeem, Omar, Voorhees, Peter, Khouri, Jack, McGuirk, Joseph, Sidana, Surbhi, Hansen, Doris K., and Patel, Krina

Published
2024
Full Text
View/download PDF

9. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Jr., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

11. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.

Author

Ghobadi, Armin, Milton, Denái, Gowda, Lohith, Rondon, Gabriela, Chemaly, Roy, Hamdi, Amir, Alousi, Amin, Afrough, Aimaz, Oran, Betul, Ciurea, Stefan, Kebriaei, Partow, Popat, Uday, Qazilbash, Muzaffar, Shpall, Elizabeth, Champlin, Richard, and Bashir, Qaiser

Subjects
Allogeneic hematopoietic stem cell transplantation, CMV, HLA-DP, Acute Disease, Adult, Aged, Cytomegalovirus, Cytomegalovirus Infections, Female, Graft vs Host Disease, HLA-DP Antigens, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Risk Factors, Transplant Recipients, Transplantation Immunology, Transplantation, Homologous, Virus Activation, Young Adult
Abstract

HLA-DP mismatched allogeneic hematopoietic stem cell transplantation (allo-HCT) is associated with increased risk of aGVHD and decreased risk of relapse with no effects on overall survival (OS). It has been proposed that CMV-reactivation induces expression of HLA-DP molecules on GVHD target tissues by releasing inflammatory cytokines. We hypothesized that the increased GVHD incidence in HLA-DP mismatched allo-SCTs correlates with recipient CMV serostatus or CMV reactivation. In addition, CMV reactivation is associated with increased risk of GVHD with an unknown mechanism. Here, we analyzed the association between HLA-DPB1 and CMV reactivation on cumulative incidence of aGVHD and relapse as well as OS in 613 patients with AML and MDS who underwent matched related or unrelated allo-HCT at MD Anderson Cancer Center from 2005 to 2011. In multivariable analysis, HLA-DPB1 mismatching was associated with increased risk of aGVHD (hazard ratio (HR): 1.53, P

Published
2019

12. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Author

Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Jr, Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, and Kaur, Gurbakhash

Published
2024
Full Text
View/download PDF

15. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Author

Varma, Ankur, Biritxinaga, Laura, Saliba, Rima M, Stich, Maximilian, Jauch, Sarah Francesca, Afrough, Aimaz, Honhar, Medhavi, Popat, Uday R, Shafi, Mehnaz A, Shah, Nina, Bashir, Qaiser, Dinh, Yvonne, Hosing, Chitra, Champlin, Richard E, and Qazilbash, Muzaffar H

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Immunology, Regenerative Medicine, Cancer, Orphan Drug, Liver Disease, Infectious Diseases, Hematology, Transplantation, Digestive Diseases, Rare Diseases, Hepatitis - B, Clinical Research, Chronic Liver Disease and Cirrhosis, Hepatitis, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adult, Aged, Case-Control Studies, Female, Hematopoietic Stem Cell Transplantation, Hepatitis B Antibodies, Humans, Incidence, Male, Middle Aged, Multiple Myeloma, Retrospective Studies, Survival Analysis, Transplantation, Autologous, Virus Activation, Multiple myeloma, Reactivation, Resolved HBV infection, Reverse seroconversion, Cardiovascular medicine and haematology
Abstract

Hepatitis B core antibody (HBcAb) seropositivity has been associated with a higher rate of hepatitis B virus (HBV) reactivation after chemotherapy, even in patients who are hepatitis B surface antigen (HBsAg) negative. However, little is known about the risk of HBV reactivation after autologous hematopoietic stem cell transplantation (auto-HCT). We evaluated the incidence of HBV reactivation, liver toxicity, and survival in patients with multiple myeloma (MM) who received auto-HCT at our institution. We retrospectively identified 107 MM patients with resolved HBV infection (HBcAb positive, HBsAg negative) and 125 patients with negative HBV serology (control subjects) who were matched for age, timing of auto-HCT from diagnosis, cytogenetics, disease status at transplant, induction therapy, and preparative regimen. All patients underwent auto-HCT between 1991 and 2013. Primary endpoints were HBV reactivation, defined as HBsAg positivity or ≥10-fold increase in HBV DNA, and hepatotoxicity, as defined in the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. In the resolved HBV infection group, 52 patients (49%) were HBsAb positive and 24 (22%) had detectable HBV DNA before auto-HCT. Only 1 patient with resolved HBV infection received pre-emptive antiviral therapy with lamivudine, whereas 4 patients received lamivudine (n = 3) or tenofovir (n = 1) at reactivation after auto-HCT for a median duration of 12 months. HBV reactivation occurred in 7 of 107 patients (6.5%) in the resolved HBV group. Median time to HBV reactivation from auto-HCT was 16 months. The cumulative incidence of grade 2 or greater hepatotoxicity was 30% in the resolved HBV infection group and 22% in the control group (hazard ratio, 1.3; 95% confidence interval, .7 to 2.3; P = .4). Nonrelapse mortality for the 2 groups was not statistically different at 2 years (P = .06), although it trended higher in the control group than in the resolved HBV infection group (8% versus 1%). The median progression-free survival (PFS) and overall survival (OS) durations in the resolved HBV infection and control groups were 21 versus 18 months (P = .5) and 53 versus 67 months (P = .2), respectively. Our data suggest that resolved HBV infection in patients undergoing auto-HCT for MM is associated with a low risk of HBV reactivation and hepatotoxicity; these complications were reversible and did not adversely affect the PFS or OS.

Published
2017

17. Assessing the Predictive Value of Pre-Lymphodepletion and Infusion Endothelial Activation and Stress Index in CD19-Directed CAR-T Therapy for B-Cell Lymphoma

Author

Upreti, Harsh Vardhan, primary, Lee, Jimmy, additional, Sannareddy, Aishwarya, additional, Reves, Heather, additional, Turer, Laura, additional, Abraham, Pearl, additional, Liu, Yulun, additional, Yilmaz, Elif, additional, Wolfe, Heather, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Madanat, Yazan F., additional, Thiebaud, Julio Alvarenga, additional, Velarde, Alejandro Marino, additional, Collins, Robert H., additional, Chung, Stephen, additional, Geethakumari, Praveen Ramakrishnan, additional, Anderson, Larry D., additional, Awan, Farrukh T, additional, Afrough, Aimaz, additional, and Anderson, Julia Marie, additional

Published
2024
Full Text
View/download PDF

18. Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Author

Soomro, Mohammad Ahsen, primary, Atrash, Shebli, additional, Rashid, Aliya, additional, Wesson, William, additional, Hashmi, Mr. Hamza, additional, Afrough, Aimaz, additional, Skikne, Barry S., additional, Lutfi, Forat, additional, Mushtaq, Muhammad Umair, additional, Abdallah, Al-Ola, additional, Ahmed, Nausheen, additional, and Khaliq, Aroog, additional

Published
2024
Full Text
View/download PDF

19. Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single Center Retrospective Analysis.

Author

Sannareddy, Aishwarya, primary, Lee, Jimmy, additional, Upreti, Harsh Vardhan, additional, Turer, Laura, additional, Anderson, Julia Marie, additional, Reves, Heather, additional, Gaines, Kailee, additional, Patel, Hetalkumari, additional, Abraham, Pearl, additional, Jones, Ashley, additional, Yn, Alicia, additional, Eze, Ebubechukwu, additional, Chong, Pearlie, additional, Tessier, Jeffrey, additional, Chung, Stephen, additional, Collins, Robert H., additional, Madanat, Yazan F., additional, Wolfe, Heather, additional, Yilmaz, Elif, additional, Thiebaud, Julio Alvarenga, additional, Geethakumari, Praveen Ramakrishnan, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Anderson, Larry D., additional, Awan, Farrukh T, additional, La Hoz, Ricardo, additional, and Afrough, Aimaz, additional

Published
2024
Full Text
View/download PDF

20. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel

Author

Akhtar, Othman Salim, primary, Hashmi, Hamza, additional, Oloyede, Temitope, additional, Brazauskas, Ruta, additional, Bye, Matthew, additional, Sidana, Surbhi, additional, Hansen, Doris K, additional, Ahmed, Nausheen, additional, Ferreri, Christopher, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Dhakal, Binod, additional, Dhanda, Devender, additional, Gowda, Lohith, additional, Harrison, Melanie, additional, Kitali, Amani, additional, Landau, Heather J, additional, Mirza, Abu-Sayeef, additional, Patel, Dr. Jinalben, additional, Patwardhan, Pallavi, additional, Qazilbash, Muzaffar H., additional, Patel, Krina K., additional, Nishihori, Taiga, additional, Ganguly, Siddhartha MD, additional, Pasquini, Marcelo C., additional, Usmani, Saad Z., additional, and Freeman, Ciara Louise, additional

Published
2024
Full Text
View/download PDF

21. Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.

Author

Janakiram, Murali, primary, Khouri, Jack, additional, Castaneda, Omar, additional, Shune, Leyla, additional, Dima, Danai, additional, Kaur, Gurbakhash, additional, De Avila, Gabe, additional, Gaballa, Mahmoud, additional, Midha, Shonali, additional, Davis, James, additional, Wagner, Charlotte, additional, McGuirk, Joseph P, additional, Forsberg, Peter, additional, Reshef, Ran, additional, Lin, Yi, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Davila, Dr. Marco L., additional, Kocoglu, Mehmet H., additional, Sborov, Douglas, additional, Htut, Myo, additional, Hashmi, Hamza, additional, Sidana, Surbhi, additional, Chowdhury, Arnab, additional, Patel, Krina K., additional, Hansen, Doris K, additional, and Atrash, Shebli, additional

Published
2024
Full Text
View/download PDF

22. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Davis, James, additional, Ahmed, Nausheen, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher Sun, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2024
Full Text
View/download PDF

23. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.

Author

Dima, Danai, Goel, Utkarsh, Sannareddy, Aishwarya, Ibeh, Nnaemeka, Ullah, Fauzia, Afrough, Aimaz, Mazzoni, Sandra, Mehdi, Ali, Rudoni, Joslyn, Raza, Shahzad, De Simone, Nicole, Williams, Louis, Khan, Adeel, Rashid, Aliya, Rice, Mikhaila, Ricci, Kristin, Samaras, Christy, Valent, Jason, Anderson, Larry D., and Anwer, Faiz

Subjects
PLASMA exchange (Therapeutics), TREATMENT effectiveness, MULTIPLE myeloma, IMMUNOGLOBULIN light chains, KIDNEY diseases
Abstract

Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell‐directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi‐institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC. At 3 months from TPE initiation, the overall hematologic response rate (ORR) was 67.5% with a very good partial response or better (≥VGPR) rate of 40%. At 6 months, ORR was 57.5%, with ≥VGPR rate of 49%. The renal response rate at 3 and 6 months was 47.5% and 43.75%, respectively; the overall renal response rate was 48.75%. On multivariable analysis, every one unit increase in baseline creatinine (odds ratio [OR] 0.76, p = 0.006), and achievement of ≥VGPR (OR 21.7 p < 0.0001) were significantly associated with renal response. Also, a ≥50% drop in sFLC was favorably associated with renal response (OR 3.39, p = 0.09). With a median follow‐up of 36.4 months, the median overall survival (OS) was 11 months. On multivariable analysis, achievement of renal response (hazard ratio [HR] 0.3, p < 0.0001) and newly diagnosed disease (NDMM; HR 0.43, p = 0.0055) were associated with improved OS. Among NDMM patients, those treated with daratumumab‐based regimens had a trend for better OS (p = 0.15), compared to other regimens, but the difference was not significant. At the end of follow‐up, an estimated 40.4% of patients who were on dialysis were able to become dialysis independent. In conclusion, our study highlights the poor survival of patients with MCN. Achievement of early renal response is crucial for prolonged OS, with daratumumab‐based therapies showing promise. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium

Author

Afrough, Aimaz, primary, Hashmi, Hamza, additional, Hansen, Doris, additional, Sidana, Surbhi, additional, Ahn, Chul, additional, Peres, Lauren, additional, Dima, Danai, additional, Freeman, Ciara, additional, Puglianini, Omar Castaneda, additional, Kocoglu, Mehmet, additional, Atrash, Shebli, additional, Voorhees, Peter, additional, Shune, Leyla, additional, McGuirk, Joseph, additional, Simmons, Gary, additional, Sborov, Douglas, additional, Davis, James, additional, Kaur, Gurbakash, additional, Sannareddy, Aishwarya, additional, Ferreri, Christopher, additional, Gaballa, Mahmoud, additional, Janakiram, Murali, additional, nadeem, omar, additional, Midha, Shonali, additional, Wagner, Charlotte, additional, Locke, Frederick, additional, Patel, Krina, additional, Khouri, Jack, additional, Anderson, Larry, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

25. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Author

Dima, Danai, primary, Davis, James A., additional, Ahmed, Nausheen, additional, Jia, Xuefei, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Abdallah, Al-Ola, additional, and Hashmi, Hamza, additional

Published
2023
Full Text
View/download PDF

26. Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Author

Wagner, Charlotte B, primary, Sweiss, Karen, additional, Anto, Eric, additional, Gonzalez, Rebecca, additional, Castaneda Puglianini, Omar Alexis, additional, Freeman, Ciara Louise L., additional, Ionescu, Filip, additional, Patel, Krina K., additional, Ferreri, Christopher, additional, Gaballa, Mahmoud, additional, Shune, Leyla, additional, McGuirk, Joseph P, additional, Sidana, Surbhi, additional, Hovanky, Vanna, additional, Khouri, Jack, additional, Dima, Danai, additional, Hashmi, Hamza, additional, Davis, James A, additional, Afrough, Aimaz, additional, Kaur, Gurbakhash, additional, Anderson, Larry D., additional, Forsberg, Peter A., additional, Herr, Megan, additional, Hansen, Doris K., additional, Sborov, Douglas, additional, and Kocoglu, Mehmet H., additional

Published
2023
Full Text
View/download PDF

28. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation

Author

Afrough, Aimaz, Pasvolsky, Oren, Ma, Junsheng, Srour, Samer, Bashir, Qaiser, Saini, Neeraj, Hosing, Chitra, Popat, Uday R., Kebriaei, Partow, Delgado, Ruby, Ullah, Muhammad R., Murphy, Regan, Manasanch, Elisabet E., Lee, Hans C., Kaufman, Gregory P., Patel, Krina K., Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Published
2022
Full Text
View/download PDF

29. Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma

Author

Afrough, Aimaz, primary, Atrash, Shebli, additional, Paul, Barry, additional, Ouchveridze, Evguenia, additional, Ahmed, Nausheen, additional, Mahmoudjafari, Zahra, additional, Bashir, Anam, additional, Alkharabsheh, Omar, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2023
Full Text
View/download PDF

31. HL-456 A Retrospective Analysis of Impact of EBV Status on Outcomes in Hodgkin Lymphoma

Author

Yilmaz, Elif, primary, Reves, Heather, additional, Afrough, Aimaz, additional, Alvarenga, Julio, additional, Anderson, Larry, additional, Collins, Robert, additional, Chung, Stephen, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Madanat, Yazan, additional, Mallik, Alka, additional, Wolfe, Heather, additional, Ramakrishnan, Praveen, additional, and Awan, Farrukh T., additional

Published
2023
Full Text
View/download PDF

32. POSTER: HL-456 A Retrospective Analysis of Impact of EBV Status on Outcomes in Hodgkin Lymphoma

Author

Yilmaz, Elif, primary, Reves, Heather, additional, Afrough, Aimaz, additional, Alvarenga, Julio, additional, Anderson, Larry, additional, Collins, Robert, additional, Chung, Stephen, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Madanat, Yazan, additional, Mallik, Alka, additional, Wolfe, Heather, additional, Ramakrishnan, Praveen, additional, and Awan, Farrukh T., additional

Published
2023
Full Text
View/download PDF

33. P-002 Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the U.S. myeloma CAR T consortium

Author

Afrough, Aimaz, primary, Hashmi, Hamza, additional, Hansen, Doris, additional, Sidana, Surbhi, additional, Ahn, Chul, additional, Dima, Danai, additional, Freeman, Ciara, additional, Puglianini, Omar Castaneda, additional, Kocoglu, M Hakan, additional, Atrash, Shebli, additional, Voorhees, Peter, additional, Shune, Leyla, additional, Simmons, Gary, additional, Sborov, Douglas, additional, Ferreri, Christopher, additional, Wagner, Charlotte, additional, Patel, Krina, additional, Khouri, Jack, additional, Anderson, Larry, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

35. Abstract A23: Less is more: Ultra-low input sequencing allows for evaluation of stem cells as a predictor of post-transplant relapse in the myelodysplastic syndromes

Author

Kroger, Benjamin, primary, Huang, Yi, additional, Patel, Prapti, additional, Afrough, Aimaz, additional, Kaur, Gurbakhash, additional, Anderson, Larry, additional, Awan, Farrukh, additional, Ramakrishnan, Praveen, additional, Verma, Kunal, additional, Vittrup, Russell, additional, Collins, Robert H, additional, Vusirikala, Madhuri, additional, Madanat, Yazan F, additional, Sallman, David, additional, Gurnari, Carmelo, additional, Maciejewski, Jaroslaw, additional, Tamari, Roni, additional, and Chung, Stephen, additional

Published
2023
Full Text
View/download PDF

36. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study

Author

Akhtar, Othman Salim, Oloyede, Temitope, Brazauskas, Ruta, Afrough, Aimaz, Hashmi, Hamza, Sidana, Surbhi, Ahmed, Nausheen, Bye, Matthew, Hansen, Doris, Ferreri, Christopher, Dhakal, Binod, Dhanda, Devender, Harrison, Melanie, Kitali, Amani, Landau, Heather, Mirza, Abu-Sayeef, Patel, Jinalben, Patwardhan, Pallavi, Qazilbash, Muzaffar, Patel, Krina, Nishihori, Taiga, Ganguly, Siddhartha, Gowda, Lohith, Anderson, Larry D., Jr., Pasquini, Marcelo C., Usmani, Saad, and Freeman, Ciara Louise

Published
2024
Full Text
View/download PDF

40. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Author

Hansen, Doris K., primary, Sidana, Surbhi, additional, Peres, Lauren C., additional, Colin Leitzinger, Christelle, additional, Shune, Leyla, additional, Shrewsbury, Alexandria, additional, Gonzalez, Rebecca, additional, Sborov, Douglas W., additional, Wagner, Charlotte, additional, Dima, Danai, additional, Hashmi, Hamza, additional, Kocoglu, Mehmet H., additional, Atrash, Shebli, additional, Simmons, Gary, additional, Kalariya, Nilesh, additional, Ferreri, Christopher, additional, Afrough, Aimaz, additional, Kansagra, Ankit, additional, Voorhees, Peter, additional, Baz, Rachid, additional, Khouri, Jack, additional, Alsina, Melissa, additional, McGuirk, Joseph, additional, Locke, Frederick L., additional, and Patel, Krina K., additional

Published
2023
Full Text
View/download PDF

41. Abstract 5925: Prevalence of clonal hematopoiesis in patients with monoclonal gammopathy of undetermined significance

Author

Quaney, Vianey, primary, Kroger, Benjamin, additional, Sannareddy, Aishwarya, additional, Khan, Umar, additional, Kalkan, Fatma, additional, Collins, Robert H., additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Huang, Yi, additional, Awan, Farrukh T., additional, Ramakrishnan, Praveen, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Chung, Stephen S., additional, and Kaur, Gurbakhash, additional

Published
2023
Full Text
View/download PDF

43. Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort

Author

Premnath, Naveen, primary, Chung, Stephen S., additional, Weinberg, Olga K., additional, Ikpefan, Ruth, additional, Pandey, Mohak, additional, Kaur, Gurbakhash, additional, Geethakumari, Praveen Ramakrishnan, additional, Afrough, Aimaz, additional, Awan, Farrukh T., additional, Anderson, Larry D., additional, Vusirikala, Madhuri, additional, Collins, Robert H., additional, Chen, Weina, additional, Agathocleous, Michalis, additional, and Madanat, Yazan F., additional

Published
2023
Full Text
View/download PDF

44. Infectious Complications Post-CAR T-Cell Therapy for Lymphomas: Impact of Bridging Therapy

Author

Lue, Brian Ko-Hung, primary, Patel, Akshat Maneesh, additional, Reves, Heather, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Chung, Stephen, additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Kumar, Kiran, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, Tessier, Jeffrey M, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

45. Impact of Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL): A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Author

Reves, Heather, primary, Jackson, Meredith, additional, Prasad, Tanushree, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Wolfe, Heather, additional, Yilmaz, Elif, additional, Khan, Adeel, additional, Kumar, Kiran, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

46. ‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies

Author

Sannareddy, Aishwarya, primary, Reves, Heather, additional, Narasimhan, Madhusudhanan, additional, Jaleta, Kefyalew, additional, Anderson, Julia Marie, additional, Patel, Hetalkumari, additional, Anderson, Larry D., additional, Afrough, Aimaz, additional, Chung, Stephen, additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Kumar, Kiran A, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, Muthukumar, Alagar R, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

47. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience

Author

Sidana, Surbhi, primary, Peres, Lauren, additional, Hashmi, Hamza, additional, Hosoya, Hitomi, additional, Ferreri, Christopher, additional, Atrash, Shebli, additional, Khouri, Jack, additional, Voorhees, Peter M., additional, Dima, Danai, additional, Simmons, Gary Lee, additional, Kalariya, Nilesh, additional, Hovanky, Vanna, additional, Bharadwaj, Sushma, additional, Arai, Sally, additional, Miklos, David B., additional, Wagner, Charlotte, additional, Davis, James, additional, Sborov, Douglas, additional, Nishihori, Taiga, additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Gonzalez, Rebecca, additional, Kocoglu, Mehmet H., additional, Sannareddy, Aishwarya, additional, Afrough, Aimaz, additional, McGuirk, Joseph P., additional, Shune, Leyla, additional, Patel, Krina K., additional, and Hansen, Doris K, additional

Published
2023
Full Text
View/download PDF

48. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation

Author

Afrough, Aimaz, Saliba, Rima M., Hamdi, Amir, El Fakih, Riad, Varma, Ankur, Dinh, Yvonne T., Rondon, Gabriela, Cornelison, A. Megan, Shah, Nina D., Bashir, Qaiser, Shah, Jatin J., Hosing, Chitra, Popat, Uday, Orlowski, Robert Z., Champlin, Richard E., Parmar, Simrit, and Qazilbash, Muzaffar H.

Published
2015
Full Text
View/download PDF

49. 3106 – RESIDUAL MUTANT HEMATOPOIETIC STEM CELLS DRIVES POST-TRANSPLANT RELAPSE OF THE MYELODYSPLASTIC SYNDROMES

Author

Kroger, Benjamin, primary, Son, Albert, additional, Huang, Yi, additional, Patel, Prapti, additional, Afrough, Aimaz, additional, Kaur, Gurbakhash, additional, Anderson, Larry, additional, Awan, Farrukh, additional, Ramakrishnan, Praveen, additional, Verma, Kunal, additional, Vittrup, Russell, additional, Collins, Robert, additional, Vusirikala, Madhuri, additional, Madanat, Yazan, additional, Gurnari, Carmelo, additional, Maciejewski, Jaroslaw, additional, Tamari, Roni, additional, and Chung, Stephen, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results